WO2003105890A3 - Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles - Google Patents

Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles Download PDF

Info

Publication number
WO2003105890A3
WO2003105890A3 PCT/EP2003/006094 EP0306094W WO03105890A3 WO 2003105890 A3 WO2003105890 A3 WO 2003105890A3 EP 0306094 W EP0306094 W EP 0306094W WO 03105890 A3 WO03105890 A3 WO 03105890A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
vesciles
mixtures
outer membrane
meningococcal
Prior art date
Application number
PCT/EP2003/006094
Other languages
French (fr)
Other versions
WO2003105890A2 (en
Inventor
Morales Ramon Faustino Barbera
Pierre Michel Desmons
Alvarez Francisco Je Dominguez
Jan Poolman
Original Assignee
Glaxosmithkline Biolog Sa
Inst Finlay
Morales Ramon Faustino Barbera
Pierre Michel Desmons
Alvarez Francisco Je Dominguez
Jan Poolman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Inst Finlay, Morales Ramon Faustino Barbera, Pierre Michel Desmons, Alvarez Francisco Je Dominguez, Jan Poolman filed Critical Glaxosmithkline Biolog Sa
Priority to US10/529,064 priority Critical patent/US20060110412A1/en
Priority to AU2003236734A priority patent/AU2003236734A1/en
Priority to BR0311777-4A priority patent/BR0311777A/en
Priority to CA002488782A priority patent/CA2488782A1/en
Priority to JP2004512791A priority patent/JP2005531614A/en
Priority to EP03735599A priority patent/EP1565211A2/en
Priority to MXPA04012568A priority patent/MXPA04012568A/en
Publication of WO2003105890A2 publication Critical patent/WO2003105890A2/en
Publication of WO2003105890A3 publication Critical patent/WO2003105890A3/en
Priority to IL16569304A priority patent/IL165693A0/en
Priority to NO20050132A priority patent/NO20050132L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to vaccine compositions for the effective prevention or treatment of neisserial, preferably meningococcal, disease. The vaccines of the invention comprise a multivalent meningococcal bled composition comprising at least one bleb with homologous bactericidal activity which is derived from a meningococcal strain with a serosubtype that is prevalent in a country of use, and at least one bleb with heterologous bactericidal activity which is derived from a meningococcal strain which need not have a serosubtype that is prevalent in the country of use.
PCT/EP2003/006094 2002-06-13 2003-06-10 Vaccine composition WO2003105890A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US10/529,064 US20060110412A1 (en) 2002-06-13 2003-06-10 Vaccine composition
AU2003236734A AU2003236734A1 (en) 2002-06-13 2003-06-10 Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles
BR0311777-4A BR0311777A (en) 2002-06-13 2003-06-10 Multivalent meningococcal vesicle composition, vaccine for treatment of neisserial disease, methods for manufacturing multivalent meningococcal vesicle composition and for prevention or treatment of neisserial disease, and use of an immunologically effective amount of the vaccine
CA002488782A CA2488782A1 (en) 2002-06-13 2003-06-10 Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles
JP2004512791A JP2005531614A (en) 2002-06-13 2003-06-10 Vaccine composition
EP03735599A EP1565211A2 (en) 2002-06-13 2003-06-10 Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles
MXPA04012568A MXPA04012568A (en) 2002-06-13 2003-06-10 Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles.
IL16569304A IL165693A0 (en) 2002-06-13 2004-12-09 Vaccine composition
NO20050132A NO20050132L (en) 2002-06-13 2005-01-11 Vaccine composition comprising blend of multivalent meningococcal outer membrane vesicles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0213622.4 2002-06-13
GBGB0213622.4A GB0213622D0 (en) 2002-06-13 2002-06-13 Vaccine Corporation

Publications (2)

Publication Number Publication Date
WO2003105890A2 WO2003105890A2 (en) 2003-12-24
WO2003105890A3 true WO2003105890A3 (en) 2004-03-25

Family

ID=9938532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/006094 WO2003105890A2 (en) 2002-06-13 2003-06-10 Vaccine composition

Country Status (20)

Country Link
US (1) US20060110412A1 (en)
EP (1) EP1565211A2 (en)
JP (1) JP2005531614A (en)
KR (1) KR20050049431A (en)
CN (1) CN100387298C (en)
AR (1) AR040204A1 (en)
AU (1) AU2003236734A1 (en)
BR (1) BR0311777A (en)
CA (1) CA2488782A1 (en)
CL (1) CL2003001192A1 (en)
CU (1) CU23552A1 (en)
GB (1) GB0213622D0 (en)
MX (1) MXPA04012568A (en)
NO (1) NO20050132L (en)
NZ (1) NZ560766A (en)
PE (1) PE20040562A1 (en)
RU (1) RU2005100509A (en)
UY (1) UY27843A1 (en)
WO (1) WO2003105890A2 (en)
ZA (1) ZA200409547B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936261B2 (en) 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
AU2006208208B2 (en) 2005-01-27 2011-05-19 Children's Hospital & Research Center At Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
EP3020411A1 (en) * 2005-12-22 2016-05-18 GlaxoSmithKline Biologicals s.a. Vaccine
WO2008028957A2 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccine
PL2200642T3 (en) 2007-10-19 2012-09-28 Novartis Ag Meningococcal vaccine formulations
JP2011503104A (en) 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー Immunomodulatory compounds and related compositions and methods
KR101667620B1 (en) * 2008-02-01 2016-10-19 사노피 파스퇴르 리미티드 Assay for diagnosing Streptococcus pneumoniae
US8466167B2 (en) 2008-03-03 2013-06-18 Irm Llc Compounds and compositions as TLR activity modulators
BRPI0923006A2 (en) 2008-12-17 2016-03-08 Novartis Ag meningococcal vaccines including hemoglobin receptor
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
WO2011024071A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
JO3257B1 (en) 2009-09-02 2018-09-16 Novartis Ag Compounds and compositions as tlr activity modulators
CA2772916C (en) 2009-09-02 2019-01-15 Novartis Ag Immunogenic compositions including tlr activity modulators
CN102573904B (en) * 2009-10-08 2016-02-10 阿昂梅迪克斯公司 Containing the composition and use thereof of extracellular vesicles coming from room air
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
CN102762206A (en) 2009-12-15 2012-10-31 诺华有限公司 Homogeneous suspension of immunopotentiating compounds and uses thereof
EP2515938A4 (en) * 2009-12-22 2013-08-28 Sanofi Pasteur Ltd Immunogenic compositions
BR112012022896A2 (en) 2010-03-18 2018-03-27 Novartis Ag adjuvant vaccines for serogroup b meningococci
CN102905703B (en) 2010-03-23 2016-09-28 诺华股份有限公司 As TLR2 agonist for treating compound (lipopeptid based on cysteine) and the compositions of infection, inflammation, respiratory disorder etc.
ES2694100T3 (en) 2010-04-07 2018-12-18 California Institute Of Technology Vehicle to distribute a compound in a mucous membrane and compositions, procedures and related systems
US9259462B2 (en) * 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
US9657297B2 (en) 2012-02-02 2017-05-23 Glaxosmithkline Biologicals Sa Promoters for increased protein expression in meningococcus
EP2823312B1 (en) 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
RU2644340C2 (en) 2012-06-14 2018-02-08 Новартис Аг Vaccines for serogroup x meningococcus
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
WO2017031431A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College Glycolipid compositions and methods of use
CA3035320A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
IL302286A (en) * 2020-10-23 2023-06-01 Omvax Inc Compositions and methods for vaccination against neisseria gonorrhoeae
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009350A2 (en) * 1999-08-03 2001-02-08 Smithkline Beecham Biologicals S.A. Genetically engineered bleb vaccine
WO2002009643A2 (en) * 2000-07-27 2002-02-07 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510169A (en) * 1997-07-17 2001-07-31 ノース アメリカン ワクチン， インコーポレイテッド Meningococcal type B porin and H. Immunogenic conjugates comprising influenzae polysaccharides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009350A2 (en) * 1999-08-03 2001-02-08 Smithkline Beecham Biologicals S.A. Genetically engineered bleb vaccine
WO2002009643A2 (en) * 2000-07-27 2002-02-07 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DE KLEIJN E D ET AL: "Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age.", VACCINE. ENGLAND 14 FEB 2000, vol. 18, no. 15, 14 February 2000 (2000-02-14), pages 1456 - 1466, XP002263476, ISSN: 0264-410X *
JODAR L ET AL: "Development of vaccines against meningococcal disease", LANCET, vol. 359, no. 9316, 27 April 2002 (2002-04-27), pages 1499 - 1508, XP004350750, ISSN: 0140-6736 *
MILAGRES LUCIMAR G ET AL: "Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine", INFECTION AND IMMUNITY, vol. 66, no. 10, October 1998 (1998-10-01), pages 4755 - 4761, XP002263478, ISSN: 0019-9567 *
MOE-GR: "Differences in surface expression of NspA among Neisseria meningitidis group B strains", INFECTION AND IMMUNITY, vol. 67, no. 11, November 1999 (1999-11-01), pages 5664 - 5675, XP002266209 *
POLLARD A J ET AL: "The meningococcus tamed?", ARCHIVES OF DISEASE IN CHILDHOOD, vol. 87, no. 1, July 2002 (2002-07-01), pages 13 - 17, XP002263479, ISSN: 0003-9888 *
SACCHI CLAUDIO T ET AL: "Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997-1998: Overview and implications for vaccine development", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 39, no. 8, August 2001 (2001-08-01), pages 2897 - 2903, XP002263474, ISSN: 0095-1137 *
See also references of EP1565211A2 *
TAPPERO JORDAN W ET AL: "Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile", JAMA (JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION), vol. 281, no. 16, 28 April 1999 (1999-04-28), pages 1520 - 1527, XP009022137, ISSN: 0098-7484 *
TONDELLA MARIA LUCIA C ET AL: "Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 38, no. 9, September 2000 (2000-09-01), pages 3323 - 3328, XP002263477, ISSN: 0095-1137 *
VAN DER VOORT EILEENE ROUPPE ET AL: "Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys", VACCINE, vol. 18, no. 14, 31 January 2000 (2000-01-31), pages 1334 - 1343, XP002263475, ISSN: 0264-410X *

Also Published As

Publication number Publication date
US20060110412A1 (en) 2006-05-25
NO20050132D0 (en) 2005-01-11
RU2005100509A (en) 2006-06-10
MXPA04012568A (en) 2005-09-21
ZA200409547B (en) 2006-07-26
BR0311777A (en) 2005-03-29
JP2005531614A (en) 2005-10-20
CN1668329A (en) 2005-09-14
KR20050049431A (en) 2005-05-25
EP1565211A2 (en) 2005-08-24
NZ560766A (en) 2009-09-25
CN100387298C (en) 2008-05-14
UY27843A1 (en) 2003-12-31
CL2003001192A1 (en) 2005-01-07
AU2003236734A1 (en) 2003-12-31
NO20050132L (en) 2005-02-11
WO2003105890A2 (en) 2003-12-24
GB0213622D0 (en) 2002-07-24
AR040204A1 (en) 2005-03-16
PE20040562A1 (en) 2004-10-19
CU23552A1 (en) 2010-07-20
CA2488782A1 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
WO2003105890A3 (en) Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles
MX349481B (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
WO2004015099A3 (en) Vaccine composition comprising lipooligosaccharide with reduced phase variability
MX2009006760A (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
BR0112928A (en) Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
BRPI0607374A2 (en) gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
UA99659C2 (en) Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
WO2007144317A3 (en) Vaccine
WO2004094596A8 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
IN2014DN08830A (en)
NZ593674A (en) Meningococcal vaccines including hemoglobin receptor
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
MY144492A (en) Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
ATE503491T1 (en) IMPROVED ANTHRAX VACCINES AND DELIVERY METHODS
WO2002060936A3 (en) Vaccine and compositions for the prevention and treatment of neisserial infections
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
WO2006057755A3 (en) Compositions containing cotinus coggygria extract and use thereof on mucosal tissues
EP1303300A4 (en) Compositions and methods for treatment of candidiasis
BRPI0414073A (en) method for inducing an immune response against rotavirus infection from a rotavirus serotype, and use of an attenuated rotavirus strain of a serotype
WO2008075983A3 (en) Analogues of phosphatidylinositol mannosides
DE602005021873D1 (en) NEW VACCINE ADJUVANT AND ITS MANUFACTURE AND USE
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
EP4327815A3 (en) Probiotics for regulating blood glucose
WO2004067718A3 (en) Necrosis-deficient mutants of tuberculosis bacteria

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004/09547

Country of ref document: ZA

Ref document number: 200409547

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2488782

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003735599

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020047019991

Country of ref document: KR

Ref document number: 2778/CHENP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004512791

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/012568

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003236734

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20038162822

Country of ref document: CN

Ref document number: 537578

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: DZP2005000013

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 2005100509

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A20050036

Country of ref document: BY

WWP Wipo information: published in national office

Ref document number: 1020047019991

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006110412

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10529064

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003735599

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10529064

Country of ref document: US